| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2006;37:1307.)
© 2006 American Heart Association, Inc.
Original Contributions |
From the Medicinal Research Laboratories (T.O., Y.T., N.M., C.K., S.Y., S.N.) and the Medicinal Development Research Laboratories (T. Sakurai, M.F., K.H., T.M., S.O.), Taisho Pharmaceutical Co, Ltd, Saitama, Japan; Shin Nippon Biomedical Laboratories Ltd (T. Susumu), Kagoshima, Japan; Cardiovascular Research Center (D.R.H.) and the Department of Physiology (R.J.R.), Medical College of Wisconsin, Milwaukee, Wisc.
Correspondence to Tomohiro Omura, PhD, 1-403 Yoshino-cho, Kita-ku, Saitama-shi, Saitama 331-9530, Japan. E-mail t.omura{at}po.rd.taisho.co.jp
Background and Purpose Arachidonic acid that is released following cerebral ischemia can be metabolized to 20-hydroxyeicosatetraenoic acid (20-HETE). 20-HETE is a potent vasoconstrictor that may contribute to ischemic injury. This study examined the effects of blockading the synthesis of 20-HETE with TS-011 on infarct size after transient occlusion of the middle cerebral artery (MCAO) of rats and after thromboembolic stroke in monkeys.
Methods Rats were treated with TS-011 or vehicle at various times after MCAO. Infarct size was measured by 2,3,5-triphenyltetrazolium chloride (TTC) staining and plasma levels of 20-HETE were determined by liquid chromatography mass spectrometry (LC/MS). The effect of TS-011 on infarct size was also studied in monkeys after introduction of a clot into the internal carotid artery.
Results Plasma levels of 20-HETE increased after MCAO in rats. TS-011 (0.01 to 1.0 mg/kg per hour) reduced infarct volume by 40%. Chronic administration of TS-011 for 7 days reduced neurological deficits after MCAO in rats. TS-011 given in combination with tissue plasminogen activator also improved neurological outcome in the stroke model in monkeys.
Conclusion These results suggest that blockade of the formation of 20-HETE with TS-011 may be useful for the treatment of ischemic stroke.
Key Words: 20-HETE brain injury cytochrome P450 ischemic stroke
This article has been cited by other articles:
![]() |
C. Fava, M. Montagnana, P. Almgren, L. Rosberg, G. Lippi, B. Hedblad, G. Engstrom, G. Berglund, P. Minuz, and O. Melander The V433M Variant of the CYP4F2 Is Associated With Ischemic Stroke in Male Swedes Beyond Its Effect on Blood Pressure Hypertension, August 1, 2008; 52(2): 373 - 380. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Nilakantan, C. Maenpaa, G. Jia, R. J. Roman, and F. Park 20-HETE-mediated cytotoxicity and apoptosis in ischemic kidney epithelial cells Am J Physiol Renal Physiol, March 1, 2008; 294(3): F562 - F570. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Roman and J. H. Lombard Does 20-Hydroxyeicosatetraenoic Acid Contribute to Sex Differences in Cardiovascular Risk by Increasing Oxidative Stress? Hypertension, July 1, 2007; 50(1): 37 - 38. [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |